H.C. Wainwright analyst Robert Burns raised the firm’s price target on SpringsWorks Therapeutics to $105 from $99 and keeps a Buy rating on the shares following the 2022 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SWTX:
- SpringsWorks Therapeutics reports Q4 EPS ($1.19), consensus ($1.22)
- SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
- SpringsWorks announces FDA acceptance, priority review of nirogacestat NDA
- SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors
- SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference